Reviewed Dr. Safa's feedback on FPCN's protocol for immediate initiation of ART (iART). Each comment on the protocol was reviewed and discussed, including the recent inclusion of Biktarvy as a first-line medication for ART in pregnant people, and alternative ART regimens to avoid resistance in those with HIV who have recently used injectable PrEP or have seroconverted on injectable PrEP. Dr. Safa reviewed a de-identified case of serconversion on injectable PrEP from his own practice to illustrate several risk factors for acquiring HIV even with perfect Apretude use. FPCN agreed to continue attending monthly meetings with Dr. Safa for education, case review and protocol discussion.
